Xoma Neuprex License Lifts Stock As Investors Return To Small-Cap Biotech
Executive Summary
Xoma returned to favor on Wall Street with a $35 mil. licensing deal for Neuprex (rBPI-21), giving Baxter worldwide rights to the bactericidal/permeability-increasing protein product for meningococcemia and all future antibacterial and anti-endotoxin indications.